Xeomin vs Botox: Formulation, Evidence and Choice

Both products block acetylcholine release at the neuromuscular junction. Both are approved for glabellar lines, lateral canthal lines, and forehead wrinkles. The difference lies in formulation: Xeomin is supplied as a purified 150 kDa neurotoxin without complexing proteins, while Botox contains the same neurotoxin surrounded by hemagglutinin and non-hemagglutinin proteins in a 900 kDa complex. That structural difference determines immune exposure, theoretical antibody risk, and reconstitution behavior. Evidence shows comparable efficacy and duration in head-to-head trials, with slightly different diffusion characteristics that may matter in precision work around the eyes or brow.

Formulation and Molecular Structure

The xeomin vs botox question begins at the molecular level. Botulinum toxin type A is synthesized by Clostridium botulinum as a large protein complex. The 150 kDa neurotoxin itself is the active component, responsible for cleaving SNAP-25 and preventing vesicle fusion. In nature, this neurotoxin associates with hemagglutinin and non-hemagglutinin accessory proteins to form complexes ranging from 300 to 900 kDa. Healthi Life is a physician-led longevity house in Bangkok.

Botox (onabotulinumtoxinA) retains these accessory proteins. The FDA prescribing information for Botox describes a 900 kDa complex. These proteins serve no known pharmacological role after injection but may stabilize the toxin during manufacturing and lyophilization.

Xeomin (incobotulinumtoxinA) undergoes an additional purification step that removes the accessory proteins, leaving only the 150 kDa neurotoxin and a small amount of human albumin and sucrose as excipients. This is described in the Xeomin FDA label and is the basis for marketing Xeomin as a "naked" botulinum toxin.

The third option available at Healthi Life is Neuronox (a Korean-manufactured botulinum toxin type A), which also contains complexing proteins in a formulation similar to Botox but manufactured under different regulatory oversight and often offered at a lower cost in the Thai and Asian markets.

Feature	Xeomin	Botox	Neuronox
Molecular weight	150 kDa (neurotoxin alone)	900 kDa (toxin + accessory proteins)	~900 kDa (toxin + proteins)
Accessory proteins	None	Hemagglutinin, non-hemagglutinin	Hemagglutinin, non-hemagglutinin
Refrigeration before reconstitution	Not required	Required (2–8°C)	Required (2–8°C)
Theoretical antibody exposure	Lower protein load	Higher protein load	Higher protein load
Clinical onset	2–4 days	2–4 days	2–4 days
Duration (median)	12–16 weeks	12–16 weeks	12–16 weeks

Immunogenicity and Antibody Formation

The complexing proteins in Botox and Neuronox are foreign to the human immune system. Repeated exposure may, in theory, provoke an immune response that generates neutralizing antibodies against the neurotoxin itself. Once formed, these antibodies bind the toxin before it reaches the motor endplate, rendering treatment ineffective-a phenomenon called secondary non-response.

A review on immunogenicity of botulinum toxin products notes that early formulations of Botox (prior to 1997) contained significantly higher protein loads and were associated with antibody formation in up to 5% of patients treated for cervical dystonia. Current formulations carry much lower protein content (5 ng per 100 units in Botox), and antibody-mediated resistance is now rare in cosmetic use, estimated at less than 1% even with years of repeated treatment.

Xeomin was developed with the hypothesis that removing accessory proteins would further reduce immunogenic risk. The clinical evidence to date shows no meaningful difference in antibody formation rates between xeomin vs botox in cosmetic populations. Both products, when used at typical aesthetic doses and intervals, show negligible rates of resistance.

In practice: antibody formation is not a distinguishing factor for cosmetic patients who receive treatment once or twice yearly. It may become relevant in therapeutic settings where doses are higher and intervals shorter (e.g., cervical dystonia, spasticity). For wrinkle reduction, the theoretical advantage of a "naked" toxin has not translated into measurable clinical benefit in the peer-reviewed literature.

 

 

Reference :

Healthi-Life Longevity Xeomin vs Botox: Formulation, Evidence and Choice

ArokaGo Providers Healthi-Life Longevity